InspireMD (NYSE:NSPR) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a research note published on Monday morning. The brokerage issued a sell rating on the stock.

Other equities research analysts have also recently issued reports about the company. Piper Sandler reissued an “overweight” rating and issued a $4.50 price objective on shares of InspireMD in a research report on Tuesday, September 17th. Lake Street Capital initiated coverage on shares of InspireMD in a research report on Wednesday, December 11th. They issued a “buy” rating and a $5.00 price target on the stock.

InspireMD Price Performance

Shares of NYSE:NSPR opened at $2.65 on Monday. The stock has a market capitalization of $69.12 million, a P/E ratio of -3.53 and a beta of 0.99. The business has a 50-day moving average of $2.77 and a two-hundred day moving average of $2.71. InspireMD has a fifty-two week low of $1.81 and a fifty-two week high of $3.42.

InspireMD (NYSE:NSPR) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. The business had revenue of $1.81 million during the quarter, compared to analysts’ expectations of $1.74 million. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. During the same period in the previous year, the company earned ($0.15) earnings per share. As a group, research analysts expect that InspireMD will post -0.79 EPS for the current fiscal year.

Institutional Investors Weigh In On InspireMD

A hedge fund recently bought a new stake in InspireMD stock. Affiance Financial LLC acquired a new position in shares of InspireMD, Inc. (NYSE:NSPR) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned 0.74% of InspireMD as of its most recent filing with the Securities and Exchange Commission. 44.78% of the stock is owned by institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.